139 related articles for article (PubMed ID: 36985777)
1. The Unusual Architecture of RNA-Dependent RNA Polymerase (RdRp)'s Catalytic Chamber Provides a Potential Strategy for Combination Therapy against COVID-19.
Metwally K; Abo-Dya NE; Alahmdi MI; Albalawi MZ; Yahya G; Aljoundi A; Salifu EY; Elamin G; Ibrahim MAA; Sayed Y; Fanucchi S; Soliman MES
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985777
[TBL] [Abstract][Full Text] [Related]
2. Investigation of Simultaneous and Sequential Cooperative Homotropic Inhibitor Binding to the Catalytic Chamber of SARS-CoV-2 RNA-dependent RNA Polymerase (RdRp).
Metwally K; Abo-Dya NE; Hamdan AME; Alrashidi MN; Alturki MS; Aly OM; Aljoundi A; Ibrahim M; Soliman MES
Cell Biochem Biophys; 2023 Dec; 81(4):697-706. PubMed ID: 37658974
[TBL] [Abstract][Full Text] [Related]
3. Plant-Derived Natural Non-Nucleoside Analog Inhibitors (NNAIs) against
Naidu SAG; Mustafa G; Clemens RA; Naidu AS
J Diet Suppl; 2023; 20(2):254-283. PubMed ID: 34850656
[TBL] [Abstract][Full Text] [Related]
4. Surface plasmon resonance approach to study drug interactions with SARS-CoV-2 RNA-dependent RNA polymerase highlights treatment potential of suramin.
Mravinec M; Bajc G; Butala M
J Virol Methods; 2021 Dec; 298():114283. PubMed ID: 34534610
[TBL] [Abstract][Full Text] [Related]
5. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin.
Yin W; Luan X; Li Z; Zhou Z; Wang Q; Gao M; Wang X; Zhou F; Shi J; You E; Liu M; Wang Q; Jiang Y; Jiang H; Xiao G; Zhang L; Yu X; Zhang S; Eric Xu H
Nat Struct Mol Biol; 2021 Mar; 28(3):319-325. PubMed ID: 33674802
[TBL] [Abstract][Full Text] [Related]
7. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.
Elfiky AA; Azzam EB; Shafaa MW
Mol Divers; 2022 Feb; 26(1):171-181. PubMed ID: 33389441
[TBL] [Abstract][Full Text] [Related]
8. Biostructural Models for the Binding of Nucleoside Analogs to SARS-CoV-2 RNA-Dependent RNA Polymerase.
Prussia AJ; Chennamadhavuni S
J Chem Inf Model; 2021 Mar; 61(3):1402-1411. PubMed ID: 33655751
[TBL] [Abstract][Full Text] [Related]
9. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.
Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A
J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630
[TBL] [Abstract][Full Text] [Related]
10. Virtual Screening and Quantum Chemistry Analysis for SARS-CoV-2 RNA-Dependent RNA Polymerase Using the ChEMBL Database: Reproduction of the Remdesivir-RTP and Favipiravir-RTP Binding Modes Obtained from Cryo-EM Experiments with High Binding Affinity.
Tsuji M
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232311
[TBL] [Abstract][Full Text] [Related]
11. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an
Elfiky AA
J Biomol Struct Dyn; 2021 Jun; 39(9):3204-3212. PubMed ID: 32338164
[TBL] [Abstract][Full Text] [Related]
12. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19.
Elfiky AA
Life Sci; 2020 May; 248():117477. PubMed ID: 32119961
[TBL] [Abstract][Full Text] [Related]
13. Structural Basis of the Potential Binding Mechanism of Remdesivir to SARS-CoV-2 RNA-Dependent RNA Polymerase.
Zhang L; Zhou R
J Phys Chem B; 2020 Aug; 124(32):6955-6962. PubMed ID: 32521159
[TBL] [Abstract][Full Text] [Related]
14. Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2
Singh S; Sk MF; Sonawane A; Kar P; Sadhukhan S
J Biomol Struct Dyn; 2021 Oct; 39(16):6249-6264. PubMed ID: 32720577
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2.
Mishra A; Rathore AS
Mol Divers; 2022 Oct; 26(5):2613-2629. PubMed ID: 35000060
[TBL] [Abstract][Full Text] [Related]
16. The potential chemical structure of anti-SARS-CoV-2 RNA-dependent RNA polymerase.
Lung J; Lin YS; Yang YH; Chou YL; Shu LH; Cheng YC; Liu HT; Wu CY
J Med Virol; 2020 Jun; 92(6):693-697. PubMed ID: 32167173
[TBL] [Abstract][Full Text] [Related]
17. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
[TBL] [Abstract][Full Text] [Related]
18. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
Wakchaure PD; Ghosh S; Ganguly B
J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
[TBL] [Abstract][Full Text] [Related]
19. Suramin, penciclovir, and anidulafungin exhibit potential in the treatment of COVID-19 via binding to nsp12 of SARS-CoV-2.
Dey SK; Saini M; Dhembla C; Bhatt S; Rajesh AS; Anand V; Das HK; Kundu S
J Biomol Struct Dyn; 2022; 40(24):14067-14083. PubMed ID: 34784490
[TBL] [Abstract][Full Text] [Related]
20. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
Karthic A; Kesarwani V; Singh RK; Yadav PK; Chaturvedi N; Chauhan P; Yadav BS; Kushwaha SK
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
